Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Blood pressure increased? 772 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 772 reports of Blood pressure increased have been filed in association with MEPOLIZUMAB (Nucala). This represents 1.8% of all adverse event reports for MEPOLIZUMAB.

772
Reports of Blood pressure increased with MEPOLIZUMAB
1.8%
of all MEPOLIZUMAB reports
15
Deaths
395
Hospitalizations

How Dangerous Is Blood pressure increased From MEPOLIZUMAB?

Of the 772 reports, 15 (1.9%) resulted in death, 395 (51.2%) required hospitalization, and 3 (0.4%) were considered life-threatening.

Is Blood pressure increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 772 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Blood pressure increased?

RITUXIMAB (4,185) INFLIXIMAB (2,997) CABOZANTINIB S-MALATE (2,939) OCTREOTIDE (2,799) OMALIZUMAB (2,678) TOCILIZUMAB (2,490) METHOTREXATE (2,486) NIRAPARIB (2,464) INFLIXIMAB-DYYB (2,309) AMLODIPINE (2,282)

Which MEPOLIZUMAB Alternatives Have Lower Blood pressure increased Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Blood pressure increased Reports All Drugs Causing Blood pressure increased MEPOLIZUMAB Demographics